Anthropic’s IPO Pitch Faces Government Risk Amid Scrutiny
Anthropic aims to go public this fall, but mounting regulatory pressures risk undercutting its valuation. Investors a...
Using Index Funds In Retirement Portfolios
Using Index Funds In Retirement Portfolios discusses straightforward methods to blend broad-market index funds into retirement allocations.
18,590 articles
Dividend Safety Check: International Yields Under Review
Investors chase international dividend income, but IDV's 6-7% yield sits beside volatile cycles in oil, banks, and mi...
Yum! Brands Selling Pizza: A Cautiously Optimistic View
Yum! Brands is selling Pizza Hut in two moves, reshaping its portfolio. This could boost balance sheet strength and s...
Iran’s Only Path Survival: Nuclear Concessions Rising
Markets confront a rebalanced risk outlook as Iran signals it may push for nuclear concessions to survive. Investors ...
Morgan’s Stocks 2026: Halftime Review Hits Key Lanes
At midyear 2026, JPMorgan’s top three overweight picks show a split: one stock has cleared its upside target, while t...
Dividend King Growth Giant: J&J Faces Lilly Challenge
Johnson & Johnson and Eli Lilly reported contrasting Q1 2026 results, pitting a durable, dividend-focused giant again...
Visa: Strong Player Disruptive in Payments Landscape
Visa sits at the center of a rapidly evolving payments ecosystem. This article explains why Visa is considered a stro...
Coke Trading Steepest Premium: What History Says Next
Coke trading steepest premium to Pepsi in years has market watchers asking what’s next. This article breaks down the ...
Oklo Just Dropped 28% This Month: Are Nuclear Stocks at Risk?
Oklo has shed 28% over the past month as investors rotate away from pre-revenue nuclear developers. Utilities remain ...
Billionaire's Prediction: Market Wrong on Fed Rate Cuts Ahead
A prominent billionaire asserts the market is underestimating how far the Federal Reserve may go with rate cuts. This...
Missed Nvidia? Missed Tesla? The Marketing AI Could Win Big
A new AI-driven marketing platform is selling shares at $0.85 in a Reg A+ offering, pitched as the ChatGPT of marketi...
Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status